A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Plovdiv, Bulgaria
-
Shumen, Bulgaria
-
Sofia, Bulgaria
-
Stara Zagora, Bulgaria
-
Varna, Bulgaria
-
-
-
-
-
Tartu N/A, Estonia
-
-
-
-
-
Rabat, France
-
Tunis, France
-
-
-
-
-
Budapest, Hungary
-
Budapest N/A, Hungary
-
Debrecen, Hungary
-
Szeged, Hungary
-
Szekesfehervar, Hungary
-
Zalaegerszeg, Hungary
-
-
-
-
-
Ashkelon, Israel
-
Haifa, Israel
-
Jerusalem, Israel
-
Ramat-Gan, Israel
-
Tel Aviv, Israel
-
-
-
-
-
Riga, Latvia
-
-
-
-
-
Kaunas, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Arnhem, Netherlands
-
Capelle Aan Den Ijssel, Netherlands
-
Den Haag, Netherlands
-
Roosendaal, Netherlands
-
-
-
-
-
Bialystok, Poland
-
Bydgoszcz, Poland
-
Bytom, Poland
-
Gdansk, Poland
-
Gdynia N/A, Poland
-
Gliwice, Poland
-
Kielce, Poland
-
Koszalin, Poland
-
Krakow, Poland
-
Lodz, Poland
-
Lublin, Poland
-
Olsztyn, Poland
-
Poznan, Poland
-
Warsaw, Poland
-
-
-
-
-
Coimbra, Portugal
-
Matosinhos N/A, Portugal
-
-
-
-
-
Bacau, Romania
-
Bucuresti, Romania
-
Cluj-Napoca, Romania
-
Hunedoara, Romania
-
Iasi, Romania
-
Onesti, Romania
-
Timisoara, Romania
-
-
-
-
-
Arkhangelsk, Russian Federation
-
Balashikha, Russian Federation
-
Barnaul, Russian Federation
-
Chelyabinsk, Russian Federation
-
Ekaterinburg, Russian Federation
-
Engels Saratov Region, Russian Federation
-
Irkutsk, Russian Federation
-
Ivanovo, Russian Federation
-
Izhevsk, Russian Federation
-
Kazan, Russian Federation
-
Krasnodar, Russian Federation
-
Leningrad Region, Russian Federation
-
Lipetsk, Russian Federation
-
Moscow, Russian Federation
-
Moscow N/A, Russian Federation
-
Moscow Region, Russian Federation
-
Murmansk, Russian Federation
-
N Novgorod N/A, Russian Federation
-
Nizhny Novgorod, Russian Federation
-
Novosibirsk, Russian Federation
-
Obninsk, Russian Federation
-
Omsk, Russian Federation
-
Orel, Russian Federation
-
Petrozavodsk, Russian Federation
-
Pyatigorsk, Russian Federation
-
Rostov-Na-Donu, Russian Federation
-
Ryazan, Russian Federation
-
Samara N/A, Russian Federation
-
Smolensk, Russian Federation
-
St Petersburg N/A, Russian Federation
-
St. Petersburg, Russian Federation
-
Stavropol, Russian Federation
-
Tomsk, Russian Federation
-
Tver, Russian Federation
-
Ulianovsk, Russian Federation
-
Vladimir, Russian Federation
-
Volgograd, Russian Federation
-
Voronezh, Russian Federation
-
Yaroslavl, Russian Federation
-
-
-
-
-
Beograd, Serbia
-
Nis, Serbia
-
Sremska Kamenica, Serbia
-
-
-
-
-
Cape Town, South Africa
-
Johannesburg, South Africa
-
Kimberley, South Africa
-
Parktown, South Africa
-
Port Elizabeth, South Africa
-
Pretoria, South Africa
-
Pretoria Gauteng, South Africa
-
-
-
-
-
Bilbao Vizcaya, Spain
-
Lérida, Spain
-
Madrid, Spain
-
Santander N/A, Spain
-
Sevilla, Spain
-
-
-
-
-
Cherkassy, Ukraine
-
Chernivtsi, Ukraine
-
Dnepropetrovsk, Ukraine
-
Donetsk, Ukraine
-
Kharkov, Ukraine
-
Kiev, Ukraine
-
Lugansk, Ukraine
-
Lutsk, Ukraine
-
Odessa, Ukraine
-
Poltava, Ukraine
-
Simferopol, Ukraine
-
Uzhgorod, Ukraine
-
Vinnitsa, Ukraine
-
Zhitomir, Ukraine
-
-
-
-
-
Huddersfield, United Kingdom
-
Manchester, United Kingdom
-
Nottingham, United Kingdom
-
Sutton, United Kingdom
-
-
-
-
Alabama
-
Hoover, Alabama, United States
-
-
California
-
Fountain Valley, California, United States
-
Long Beach, California, United States
-
Los Angeles, California, United States
-
Palm Springs, California, United States
-
-
Delaware
-
Newark, Delaware, United States
-
-
Florida
-
Lakeland, Florida, United States
-
-
Georgia
-
Fort Gordon, Georgia, United States
-
-
Illinois
-
Centralia, Illinois, United States
-
Joliet, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
Louisville, Kentucky, United States
-
-
Louisiana
-
Lafayette, Louisiana, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Mississippi
-
Jackson, Mississippi, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
New Jersey
-
Newark, New Jersey, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
Bronx, New York, United States
-
Cooperstown, New York, United States
-
New York, New York, United States
-
-
North Carolina
-
Gastonia, North Carolina, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
Upland, Pennsylvania, United States
-
-
Rhode Island
-
Providence, Rhode Island, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
N Charleston, South Carolina, United States
-
-
Texas
-
Fort Worth, Texas, United States
-
Pasadena, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females with locally advanced or metastatic breast cancer who received prior anthracycline therapy in the neoadjuvant or adjuvant setting, and had at least a 12-month disease-free interval since the end of their last cytotoxic therapy, were eligible for the study
- Participants who received prior hormonal therapy, or no more than 1 cytotoxic chemotherapy regimen (anthracyclines, taxanes, or antitubulin agents were not permitted), or both for advanced disease
- Participants with normal cardiac function, as evidenced by a normal left ventricular ejection fraction
Exclusion Criteria:
- More than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer
- Treatment of advanced breast cancer with an anthracycline, paclitaxel, docetaxel, vinorelbine, or vinblastine (prior treatment of advanced breast cancer with 1 regimen that included alkylating agents or antimetabolite agents was acceptable)
- Less than 2 months since the last dose of trastuzumab
- Less than 3 weeks since last dose of tamoxifen or fulvestrant, or less than 1 week since the last dose of other hormonal therapy
- Radiation to areas of disease within 30 days before study enrollment
- History of New York Heart Association Class II or greater cardiac disease or other clinical evidence of congestive heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: DOXIL and docetaxel combination therapy
DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
|
Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Other Names:
|
|
ACTIVE_COMPARATOR: Docetaxel monotherapy
Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
|
Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Progression
Time Frame: From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled
|
Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.
|
From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled
|
Time interval in months between the date of randomization and the participant's death from any cause.
|
From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled
|
|
Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR)
Time Frame: Up to 30 to 42 days after last dose of study medication
|
Number of participants in the evaluable population who achieved a CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
CR: Disappearance of all target lesions and PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD.
Response was assessed by Computed Tomography (CT)/Magnetic Resonance Imaging (MRI).
|
Up to 30 to 42 days after last dose of study medication
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR004120
- DOXILBCA3001 (OTHER: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.